10 likes | 30 Views
The total incident population of Dravet Syndrome in the seven major markets was 30,820 in 2017. <br>Similarly, of all the Dravet Syndrome patients in the 7MM, the United States registered around 20,912 patients while Japan had nearly 2,766 patients during the year 2017.<br><br>The market size of Dravet Syndrome in 7MM in 2017 was found to be USD 79.1 Million, which is expected to grow during the forecast period 2017-2030.<br><br>Increasing research activities and increasing disease awareness are the two important factors expected to drive the Dravet Syndrome market forward in the coming years.<br><br>The key players in the Dravet Syndrome market include Zogenix, Ovid Therapeutics, PTC Therapeutics, Biocodex, GW Pharmaceuticals and others.<br><br>For more detailed information on Dravet Syndrome Market, visit: https://www.delveinsight.com/report-store/dravet-syndrome-market<br><br>#epilepsy #seizures #SUDEP #severemyoclonicepilepsyofinfancy #SMEI #geneticdisorder #RareDiseases #GeneticDisease #epilepsysyndrome #neurologicalcondition #Dravetsyndrome #childhoodepilepsy<br><br>
E N D